Timothy McAlindon, MD, MPH

Tufts Medical Center
Arlington, MA, United States

Rheumatologist and Clinical Investigator in the fields of osteoarthritis and rheumatic disorders

Disclosure information not submitted.

Presentation(s):

• 1639: A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial (OA-11) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderate to Severe Osteoarthritis Participants

  Monday, November 14, 2022
  9:00 AM – 9:10 AM Eastern Time

• 1899: A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (OA-10) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time

• 1902: Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time